| Agilent's Q2: Solid Company With Good Growth Prospects Wall Street Cheat Sheet submits: Instrumentation and measurement company Agilent (NYSE: A) reported second-quarter earnings per share of $0.43 after the bell Monday, beating analysts' estimates by $0.2 per share (see transcript). The company reported earnings per share of $0.13 for the year-ago quarter. Revenue came in at $1.27 billion, up over 16 percent from one year ago, on orders of $1.35 billion, a YOY increase of 31 percent. This is another profitable quarter for the company. In the prior quarter, revenues increased 4 percent and net income increased 23 percent. The company had a $100 million net loss in 2009 for a negative $0.29 per share.Complete Story » seekingalpha.com |
FDA to Weigh Consumer Genetic Tests A high bar is likely to be set for companies seeking to sell genetic tests directly to consumers, according to top FDA officials. online.wsj.com |
New Way to Regenerate Tissue Scientists say they got muscle tissue in mice to regenerate, essentially re-awakening an ability that had been lost over evolutionary time. It is hoped that the approach will one day offer a way to make fresh tissue and help repair damaged organs. online.wsj.com |
Nicusa Capital Calls for Leadership Changes at BioClinica [PR Newswire] - Nicusa Capital is calling for the resignations of Dr. David Nowicki as Chairman of the Board, Mr. Mark Weinstein as CEO, and Mr. Ted Kaminer as CFO of BioClinica, Inc. . Â Nicusa owns 854,119 shares, or approximately 5.6%, of the Company's shares. Â We believe that BioClinica's core imaging business is worth substantially more than the current stock price, but management's corporate strategy is flawed and is destroying shareholder value. Â We have communicated our concerns to the Board of Directors on several occasions and, in June 2010, we publicized these concerns in a 13D filing. Â us.rd.yahoo.com |
Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 [PR Newswire] - Quest Diagnostics Incorporated , the world's leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2010, income from continuing operations increased to $198 million, or $1.13 per diluted share, from $192 million, or $1.02 per diluted share, for the third quarter of 2009. us.rd.yahoo.com |